NEU
Delivery · Highdata caveat$1.7B—
Neuren Pharmaceuticals
Biotech · Neurology
Trofinetide for Rett syndrome, partnered with Acadia
Data HealthTrials1 of 2 active · stale enrollment
Cash data from Dec 2025 4C(5mo old)Figures from ASX filings · not financial advice
[ VITALS ]
Cash on Hand
$296.0M
Dec 2025 4C
Runway
—Based on Dec 2025 4C
Market Cap
$1.7B
Burn Rate
—
Dec 2025 4C
Shares Outstanding
126M
Pipeline Assets
2
3M Price
NEU.ASX$13.240+10.8% 3M
Low $11.280High $14.540
Pipeline Assets (2)
Discovery
Preclinical
Ph 1
Ph 1/2
Ph 2
Ph 2/3
Ph 3
NDA
Capital Raises & Buybacks
14 buybacks
Current shares outstanding: 126M
Buyback
Other ticker dataInsider activity, holders, grants, publications
expand ›
Insider activity, holders, grants, publications
Director Transactions
1 transactionLast 90dNo Activity
Buys0-1 vs prior
Sells0
$151,7822026-03-05
·
Catalysts (11)· 2 upcoming · 9 past
NNZ-2591 Phase 2 Phelan-McDermid interim
UpcomingExpectedarrow_upwardHigh31 July 2026
SpeculativeremoveMed31 Oct 2027
expand_more9 past catalysts
Track RecordDelivery Consistency Index
expand ›
Delivery Consistency Index
Historical delivery and spending consistency. Data is limited for recently added companies.
Delivery Consistency Index
Delivery
High92/100(limited data)
Timeline adherence · phase-adjusted tolerance · recency-weighted · min 3 catalysts
Capital discipline
–Insufficient data
Burn rate stability · stage-adjusted thresholds · runway trend · R&D focus
Hit 5 of 5 guided dates· rolling 2yr· of 11 tracked
Filing discipline not scored — this company reports under US regime (Form 10-K / 10-Q). ASX Listing Rule 4.7C deadlines don't apply.
What drove these scores · rolling 2yr
arrow_drop_up
Cash-flow positive — Capital discipline metric not applicable
·
DAYBUE royalty payment — 21d late — within 90d phase tolerance
·
Update - Notification of buy-back - NEU — Delivered on time
·
Update - Notification of buy-back - NEU — Delivered on time
·
Update - Notification of buy-back - NEU — Delivered on time
·
Update - Notification of buy-back - NEU — Delivered on time
·
Limited data adjustment — Score adjusted toward neutral (5/6 data points) — accuracy improves with more completed catalysts
Completed catalysts
✓DAYBUE royalty payment— Quarterly update filed (auto-resolved)
+21d late
✓Update - Notification of buy-back - NEU
On time
✓Update - Notification of buy-back - NEU
On time
✓Update - Notification of buy-back - NEU
On time
✓Update - Notification of buy-back - NEU
On time
Outcome quality (positive/negative readouts) reflects the science, not execution — shown above but excluded from the score.
These metrics reflect historical operational data only. They are not predictive of future performance, do not constitute investment advice, and should not be used as the basis for any investment decision.
Clinical Trials(6)
2 activeClinicalTrials.gov ↗
Ph3Recruiting
NNZ-2591
An Open-label Study of NNZ-2591 in Pediatric Participants With Phelan-McDermid Syndrome
Phelan-McDermid Syndrome
ENROL180
no manual snapshots — enter via record_enrollment.py
Ph3RecruitingEnrollment stale · 210d
NNZ-2591Placebo
A Study of NNZ-2591 in Pediatric Participants With Phelan-McDermid Syndrome
Phelan-McDermid Syndrome
RandomizedQuadruple Blind3 Years – 12 Years
Primary endpoint Efficacy of NNZ-2591 compared with placebo as measured by the Phelan-McDermid Syndrome Assessment of Change (PMSA-C) overall score.
ENROL160
no manual snapshots — enter via record_enrollment.py